Published in Arch Intern Med on September 26, 2005
The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause (2012) 4.04
Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ (2008) 3.56
A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. Neuropsychopharmacology (2006) 1.90
Physical activity, menopause, and quality of life: the role of affect and self-worth across time. Menopause (2009) 1.87
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause (2008) 1.74
Hormone therapy and physical function change among older women in the Women's Health Initiative: a randomized controlled trial. Menopause (2010) 1.48
Sleep problems after short-term hormone therapy suspension: secondary analysis of a randomized trial. Menopause (2011) 1.40
Evaluation and management of sleep disturbance during the menopause transition. Semin Reprod Med (2010) 1.39
Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med (2009) 1.21
Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: an analysis of published articles. PLoS Med (2011) 1.07
Estrous cycle, pregnancy, and parity enhance performance of rats in object recognition or object placement tasks. Reproduction (2008) 1.04
Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Womens Health (2008) 1.00
Correlates of sexual satisfaction among sexually active postmenopausal women in the Women's Health Initiative-Observational Study. J Gen Intern Med (2008) 0.99
The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis Study. Osteoporos Int (2006) 0.98
Adult female wildtype, but not oestrogen receptor beta knockout, mice have decreased depression-like behaviour during pro-oestrus and following administration of oestradiol or diarylpropionitrile. J Psychopharmacol (2008) 0.98
Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol (2013) 0.93
Relationship between menopausal symptoms and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 0.93
Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. Obstet Gynecol (2013) 0.86
Non-pharmacological treatment of insomnia. Neurotherapeutics (2012) 0.85
Divergent mechanisms for trophic actions of estrogens in the brain and peripheral tissues. Brain Res (2010) 0.84
From in vivo gene targeting of oestrogen receptors to optimization of their modulation in menopause. Br J Pharmacol (2012) 0.77
Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy. Int J Womens Health (2012) 0.77
The tissue selective estrogen complex: a promising new menopausal therapy. Pharmaceuticals (Basel) (2012) 0.76
Letter to the editor. Menopause (2010) 0.75
Oestrogen did not improve health related quality of life in postmenopausal women with hysterectomy. Evid Based Med (2006) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Implementation of the Women's Health Initiative study design. Ann Epidemiol (2003) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc (2005) 6.73
Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Pelvic organ prolapse in the Women's Health Initiative: gravity and gravidity. Am J Obstet Gynecol (2002) 5.73
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65
Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst (2005) 5.52
Effects of estrogen with and without progestin on urinary incontinence. JAMA (2005) 5.41
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA (2003) 5.26
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Effects of estrogen plus progestin on health-related quality of life. N Engl J Med (2003) 4.83
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA (2003) 4.72
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health (2006) 4.51
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative. Am J Epidemiol (2008) 4.28
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Effect of communications training on medical student performance. JAMA (2003) 3.92
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA (2004) 3.85
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60
Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). Arch Intern Med (2004) 3.59
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
Estrogen plus progestin and risk of venous thrombosis. JAMA (2004) 3.46
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control (2002) 3.27
Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials (2008) 3.24
Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med (2008) 3.12
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA (2003) 2.90
Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA (2004) 2.90
Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care (2008) 2.76
Electrocardiographic abnormalities that predict coronary heart disease events and mortality in postmenopausal women: the Women's Health Initiative. Circulation (2006) 2.64
Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA (2003) 2.62
Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts. Arch Intern Med (2009) 2.54
Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause (2010) 2.50
Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation (2007) 2.50
Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. Circulation (2005) 2.49
Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension (2008) 2.44
Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med (2008) 2.44
Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation (2006) 2.40
Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst (2007) 2.36
Symptom experience after discontinuing use of estrogen plus progestin. JAMA (2005) 2.32
Protein intake and incident frailty in the Women's Health Initiative observational study. J Am Geriatr Soc (2010) 2.28
Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab (2012) 2.25
Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. Am J Clin Nutr (2011) 2.21
Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity (Silver Spring) (2006) 2.17
Risk factors for late-life suicide: a prospective, community-based study. Am J Geriatr Psychiatry (2002) 2.13
Electrocardiographic predictors of incident congestive heart failure and all-cause mortality in postmenopausal women: the Women's Health Initiative. Circulation (2006) 2.13
Practical behavioral trials to advance evidence-based behavioral medicine. Ann Behav Med (2006) 2.05
Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci (2009) 2.01
Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol (2005) 2.01
Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med (2008) 1.94